Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 May 2007, Vol. 109, No. 9, pp. 4105.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tefferi, A.
Right arrow Articles by Wolanskyj, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tefferi, A.
Right arrow Articles by Wolanskyj, A.
Related Collections
Right arrow Neoplasia
Right arrow Clinical Trials and Observations
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

CORRESPONDENCE

The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia

To the editor:

Three recent papers have reported an association between leukocytosis and thrombosis in patients with myeloproliferative disorders; a leukocyte count of more than 15 x 109/L, as opposed to 10 x 109/L or fewer, was associated with myocardial infarction in polycythemia vera,1 and that of either 15 x 109/L2 or more or more than 8.7 x 109/L3 with thrombosis in general in essential thrombocythemia (ET). In the current study, we used the database from a previously published cohort of 605 patients with ET4 in order to clarify associations at diagnosis and prognostic relevance for subsequent thrombotic events, using both of the aforementioned leukocyte targets in ET. Arterial and venous thromboses were analyzed separately and in the context of other significant risk factors. We also looked into the interaction between leukocyte count and current smoking; previous epidemiologic studies have suggested that smoking might account for the association between leukocyte count and stroke in the general population.5

The study population included 605 patients (median age, 57 years; 66% women) with ET whose presenting clinical and laboratory features have previously been communicated in a paper that addressed risk factors for survival and leukemic transformation.4 In the current study, variables at diagnosis were evaluated for significant association with thrombosis occurring either at diagnosis or during follow-up (median 84 months). A leukocyte count of 15 x 109/L or more or more than 8.7 x 109/L was registered in 86 (14%) and 348 patients (58%) at diagnosis, respectively. Smoking history at diagnosis was documented in 128 patients (21%) and was more likely to be encountered in patients with leukocyte counts that exceeded either one of the aforementioned leukocyte targets (P = .002 and P < .001, respectively). Numbers of patients with arterial thrombosis history before diagnosis, at diagnosis, and during follow-up were 27, 104, and 133, respectively. The corresponding numbers for venous events were 36, 35, and 45. Information on JAK2V617F mutational status was available in 187 patients.

Table 1 outlines significance levels (ie, P values) during univariate and multivariable analysis of parameters at diagnosis. For arterial thrombosis at diagnosis, independent associations were demonstrated only for higher hemoglobin level and leukocytosis (using either 1 of the aforementioned leukocyte targets). A leukocyte count of 15 x 109/L or more was also associated with venous thrombosis at diagnosis. However, unlike the observations from another recent study,3 leukocyte count at presentation did not predict subsequent vascular events. However, accurate interpretation of the relationship between leukocyte count at diagnosis and subsequent thrombosis is confounded by treatment effect on both variables, and prospective studies are needed to clarify the issue further. The current study also underscores the importance of accounting for previous history of vascular events during risk factor assessment for thrombosis and discloses the specific pattern of the association in this regard.


View this table:
[in this window]
[in a new window]

 
Table 1. Risk factors for thrombosis among 605 patients with ET

 
Authorship

Correspondence: Ayalew Tefferi, Mayo Clinic, 200 First Street SW, Rochester, MN 55905; e-mail: tefferi.ayalew{at}mayo.edu.

Ayalew Tefferi, Naseema Gangat, and Alexandra Wolanskyj

References

  1. Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood Prepublished November 14, 2006, as DOI: 10.1182/2006-08-042515.

  2. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006; 81:159–166.[Abstract/Free Full Text]

  3. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and Jak2 mutation status. Blood Prepublished November 16, 2006, as DOI: 10.1182/2006-09-046342.

  4. Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 2007; 21:271–276.

  5. Gillum RF, Ingram DD, Makuc DM. White blood cell count and stroke incidence and death: the NHANES I epidemiologic follow-up study. Am J Epidemiol 1994; 139:894–902.[Abstract/Free Full Text]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
haematolHome page
F. Girodon, C. Schaeffer, C. Cleyrat, M. Mounier, I. Lafont, F. D. Santos, A. Vidal, M. Maynadie, and S. Hermouet
Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy
Haematologica, November 1, 2008; 93(11): 1723 - 1727.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
F. Passamonti, E. Rumi, L. Arcaini, E. Boveri, C. Elena, D. Pietra, S. Boggi, C. Astori, P. Bernasconi, M. Varettoni, et al.
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients
Haematologica, November 1, 2008; 93(11): 1645 - 1651.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Carobbio, E. Antonioli, P. Guglielmelli, A. M. Vannucchi, F. Delaini, V. Guerini, G. Finazzi, A. Rambaldi, and T. Barbui
Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia
J. Clin. Oncol., June 1, 2008; 26(16): 2732 - 2736.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. A. Khorana, N. M. Kuderer, E. Culakova, G. H. Lyman, and C. W. Francis
Development and validation of a predictive model for chemotherapy-associated thrombosis
Blood, May 15, 2008; 111(10): 4902 - 4907.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tefferi, A.
Right arrow Articles by Wolanskyj, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tefferi, A.
Right arrow Articles by Wolanskyj, A.
Related Collections
Right arrow Neoplasia
Right arrow Clinical Trials and Observations
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020